OP0160 Response and drug survival of 1st TNF inhibitor in 370 patients with psoriatic arthritis in a real life setting – what is the role of co-medication with methotrexate?:

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 108.2-108 ◽  
Author(s):  
K.M. Fagerli ◽  
E. Lie ◽  
D. van der Heijde ◽  
M.S. Heiberg ◽  
S. Kalstad ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Real Life ◽  
Tnf Inhibitor ◽  
Drug Survival ◽  
Real Life Setting

scholarly journals Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement

2021 ◽  
Author(s):  
Maria Sole Chimenti ◽  
Paola Conigliaro ◽  
Francesco Caso ◽  
Luisa Costa ◽  
Augusta Ortolan ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Smoking Habit ◽  
Survival Rates ◽  
Real Life ◽  
Wilcoxon Test ◽  
Cutaneous Manifestations ◽  
Drug Survival ◽  
Real Life Setting ◽  
Insufficient Response

Abstract Objectives To determine the effectiveness of golimumab (GLM) in improving joint, periarticular structures and cutaneous manifestations in patients with moderate to severe psoriatic arthritis (PsA) with cutaneous psoriasis in different real-life clinical settings and 48-month drug survival. Methods Clinical and laboratory records were collected from PsA patients treated with GLM at baseline (T0) and after 6, 12, 24, 36, and 48 months of treatment. Comparisons were performed using a paired t-test or Wilcoxon test. Drug survival rates were analyzed using Kaplan–Meier estimates. p value < 0.05 was considered statistically significant. Results Data from 105 patients were collected. PsO occurred in 80% of patients and enthesitis in 78%, peripheral and axial arthritis in 63.8% and 35.3%, respectively, while erosions in 36.2%. The main comorbidities were cardiovascular diseases (31.4%) and metabolic syndrome (MetS) (19%). A statistically significant improvement in articular and cutaneous psoriasis was registered at T48 of GLM-therapy in clinical (DAPSA p < 0.0001; PASI p < 0.01; BASDAI p < 0.0001) and laboratory (CRP < 0.05) indexes. Gender (p = 0.652), BMI (p = 0.655), smoking habit (p = 0.466), and line of treatment (p = 0.208) did not affect treatment efficacy nor persistence. At T48, 42% of patients discontinued GLM: the most frequent reason was an insufficient response or loss of efficacy (28.6%). Conclusion A 48-month GLM high drug persistence of PsA patients was observed in real-life, in patients presenting high disease activity, elevated prevalence of comorbidities, and more than one line of treatment at baseline. Patients’ characteristics as gender, smoke, BMI, different lines of treatment, and concomitant methotrexate treatment affected treatment persistence, making GLM effective and safe in moderate-severe PsA in a long-term real-life setting. Key Points• Golimumab was effective in psoriatic arthritis, including both musculoskeletal and cutaneous manifestations. • Golimumab effectiveness and drug survival were not affected by comorbidities and patient-related characteristics. • The 4-year drug survival curves confirm the efficacy and safety of golimumab in psoriatic arthritis patients in a real-life setting.

scholarly journals AB0676 THE ROLE OF ACPA AND ANA IN SPONDYLOARTHRITIS: HOW THE AUTOIMMUNE DYSREGULATION CAN AFFECT THE COURSE OF DISEASE AND THERAPEUTIC SUCCESS OF MONOTHERAPY DMARDS AND bDMARDs

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1633.1-1633
Author(s):  
D. Cici ◽  
C. Rotondo ◽  
A. Corrado ◽  
S. Berardi ◽  
N. Mansueto ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Start Time ◽  
Disease Manifestation ◽  
Therapeutic Success ◽  
Course Of Disease ◽  
Drug Survival ◽  
Comorbidity Index ◽  
Citrullinated Protein ◽  
Axial Involvement

Background:Occasional findings of anti-citrullinated-protein-antibodies (ACPA) and anti-nuclear-antibodies (ANA) were rarely described in literature on Psoriatic Arthritis (PsA) and on Spondyloarthritis (SpA) in general. How these autoimmune dysregulations can affect the course of them is not yet understood.Objectives:The aim of our study is to evaluate if the presence of ACPA and ANA can determine different disease subsets and influence the DMARDs monotherapy (methotrexate) drug survival (DSM) and b-DMARDs multi-failure patients (MF).Methods:We conducted a retrospective study on patients with Psoriatic Arthritis (PsA) and Spondyloarthritis that fulfilled the ASAS and CASPAR criteria. Patients with diagnosis of connective tissue disease and rheumatoid arthritis and patients ≤ 18 years old were excluded from the study. For each patient, the following variables were considered: age, ACPA, ANA, time between arthritis onset and start of DMARDs (start-time), DSM, switch to b-DMARDs (sw-bDMARDs), arthritis subset (oligoarticular (OA), polyarticular (PA), enthesitis (EA), axial involvement (AI)), number of comorbidities (NC), Charlson Comorbidity Index (CCI).Results:150 patients (55% with PsA and 45% with another SpA) were included in the study. No differences were found in age, ANA rate, ACPA rate, start-time, OA, PA, EA, AI, NC and CCI between the PsA and SpA groups.In the whole group of patients, the ACPA+ subjects(11%) had a significant increase of NC (2.47 ± 1.5 vs 1.6 ± 1.4, p=0.035), a trend to higher CCI, to switch to b-DMARDs, and to be MF compared to those without ACPA. In the same group, the ANA+ patients (12%) showed shorter DSM (233.5 wk ± 45.9 vs 548.0 wk ± 56.8, p=0.362) with similar trend in each subgroup (PsA and SpA).In SpA group, the ACPA+ patients(6,3%) had a trend to shorter DSM (269.0 weeks ± 125vs 603.96 wk± 92.8, p=0.492),to higher sw-bDMARDs, and to be MF, higher NC and CCI compared to those without ACPA. No differences in clinical subset (OA, PA, EA, AI) were observed. In the same group the ANA+ patients had significant higher rate of PA (100% vs 65%, p=0.026) rather than OA (0% vs 35%, p=0.025). No significant differences were found in NC, CCI, MF.In the PsA group, ACPA+ patients showed a trend to develop PA and EA subsets, shorter DSM (187.5 wk ± 48.7 vs 299.6 wk ± 31.4, p=0.415), higher rate to sw-bDMARDs and to be MF. The ANA+ PsA patients had higher trend to develop PA and AI subsets rather than OA and EA. All ANA+ patients were MF (100% vs 42%, p=0.046).Conclusion:The ACPA and ANA positivity in PsA and SpA patients could be suggestive of more severe clinical disease manifestation, higher frequency of comorbidities and lower predicted 10-year survival (CCI). Moreover, this autoimmune dysregulation could be associated with worse drug survival in monotherapy with methotrexate and higher chance to be MF. Therefore, they can be taken into account for clinical management of these patients.Disclosure of Interests:None declared

The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study

2013 ◽  
Vol 73 (1) ◽  
pp. 132-137 ◽  
Author(s):  
Karen Minde Fagerli ◽  
Elisabeth Lie ◽  
Désirée van der Heijde ◽  
Marte Schrumpf Heiberg ◽  
Åse Stavland Lexberg ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tnf Inhibitor ◽  
Inhibitor Treatment

scholarly journals Three years of methotrexate and secukinumab: Outcomes of psoriatic arthritis in a real-life setting

2021 ◽  
Author(s):  
Stefania Nicola ◽  
Silvia Gallo Cassarino ◽  
Giovanni Rolla ◽  
Giada Geronazzo ◽  
Monica Fornero ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Real Life ◽  
Real Life Setting

scholarly journals Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting

2019 ◽  
Vol 10 ◽  
Author(s):  
Mayara Costa de Camargo ◽  
Bruna Cipriano Almeida Barros ◽  
Izabela Fulone ◽  
Marcus Tolentino Silva ◽  
Miriam Sanches do Nascimento Silveira ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Psoriatic Arthritis ◽  
Adverse Events ◽  
Real Life ◽  
Biological Agents ◽  
Real Life Setting

scholarly journals Long-Term Infliximab Treatment in Psoriasis Patients: A National Multicentre Retrospective Study

2020 ◽  
Vol 2020 ◽  
pp. 1-3
Author(s):  
Clémentine Carlet ◽  
Damien Bichard ◽  
Marie Aleth Richard ◽  
Emmanuel Mahé ◽  
Clémence Saillard ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Critical Role ◽  
Real Life ◽  
Solid Cancer ◽  
Infliximab Treatment ◽  
Efficacy And Safety ◽  
Drug Survival ◽  
The Mean

Background. Although infliximab (IFX) has been available since 2005, there are very little data on the long-term drug survival of infliximab in real-life. Objective. Our aim was to identify and describe psoriasis patients treated with IFX for longer than 6 years. Methods. Psoriasis patients treated with IFX for longer than 6 years were retrospectively included. Demographic and clinical data were collected in May 2018. Results. Between January 2005 and December 2012, 43 patients were maintained on IFX for 6 years or longer. IFX was introduced as a 4.5 line of systemic therapy. The mean duration of IFX treatment was 8.5 years (6–12). In May 2018, 30 patients (70%) were still maintained on IFX at 4–6 mg/kg every 8–10 weeks with an efficiency of about 100%. IFX was stopped in 13 patients (30%) mainly for loss of efficacy in 6 patients (46%). Three patients developed solid cancer including bladder cancer, lung cancer, and prostate cancer. Limitation. Retrospective study. Conclusion. We report the efficacy and safety of IFX maintained for up to 12 years in psoriasis patients. The long-term use of IFX was associated with a high BMI confirming the critical role of weight-based dosing for this drug.

scholarly journals A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service

2019 ◽  
Vol 80 (6) ◽  
pp. 1796-1798
Author(s):  
Giuseppina Abignano ◽  
Nafisa Fadl ◽  
Mira Merashli ◽  
Claire Vandevelde ◽  
Jane Freeston ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Combination Therapy ◽  
Real Life ◽  
Real Life Setting
Sign in / Sign up

Export Citation Format

Share Document